JP2006516987A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516987A5
JP2006516987A5 JP2006502243A JP2006502243A JP2006516987A5 JP 2006516987 A5 JP2006516987 A5 JP 2006516987A5 JP 2006502243 A JP2006502243 A JP 2006502243A JP 2006502243 A JP2006502243 A JP 2006502243A JP 2006516987 A5 JP2006516987 A5 JP 2006516987A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
formula
treatment
anemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006502243A
Other languages
English (en)
Japanese (ja)
Other versions
JP5390070B2 (ja
JP2006516987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2004/000457 external-priority patent/WO2004069237A1/en
Publication of JP2006516987A publication Critical patent/JP2006516987A/ja
Publication of JP2006516987A5 publication Critical patent/JP2006516987A5/ja
Application granted granted Critical
Publication of JP5390070B2 publication Critical patent/JP5390070B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006502243A 2003-02-07 2004-02-06 赤血球形成刺激薬としての中鎖脂肪酸、グリセリド、および類似体 Expired - Fee Related JP5390070B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07
US60/445,454 2003-02-07
PCT/GB2004/000457 WO2004069237A1 (en) 2003-02-07 2004-02-06 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Publications (3)

Publication Number Publication Date
JP2006516987A JP2006516987A (ja) 2006-07-13
JP2006516987A5 true JP2006516987A5 (https=) 2007-01-18
JP5390070B2 JP5390070B2 (ja) 2014-01-15

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502243A Expired - Fee Related JP5390070B2 (ja) 2003-02-07 2004-02-06 赤血球形成刺激薬としての中鎖脂肪酸、グリセリド、および類似体

Country Status (28)

Country Link
US (1) US9682054B2 (https=)
EP (1) EP1592416B1 (https=)
JP (1) JP5390070B2 (https=)
KR (1) KR101120775B1 (https=)
CN (1) CN100427081C (https=)
AP (1) AP2005003367A0 (https=)
AR (1) AR043120A1 (https=)
AT (1) ATE419846T1 (https=)
AU (1) AU2004210193B2 (https=)
BR (1) BRPI0407276A (https=)
CA (1) CA2515160C (https=)
CY (1) CY1108963T1 (https=)
DE (2) DE04708802T1 (https=)
DK (1) DK1592416T3 (https=)
EA (1) EA009939B1 (https=)
ES (1) ES2255467T3 (https=)
IL (1) IL170057A (https=)
JO (1) JO2705B1 (https=)
MA (1) MA27664A1 (https=)
MX (1) MXPA05008382A (https=)
MY (1) MY140913A (https=)
NO (1) NO334085B1 (https=)
NZ (1) NZ541593A (https=)
PT (1) PT1592416E (https=)
SI (1) SI1592416T1 (https=)
TN (1) TNSN05189A1 (https=)
WO (1) WO2004069237A1 (https=)
ZA (1) ZA200506246B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158322A0 (en) * 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
KR20070063507A (ko) * 2004-09-03 2007-06-19 프로메틱 바이오사이언시즈 인코포레이티드 면역조절작용과 화학방어활성을 가진 치환된 퓨리닐 유도체및 단독 또는 중쇄 길이 지방산이나 글리세리드와의 혼합사용
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
MX2007003967A (es) * 2004-10-01 2008-03-04 Prometic Biosciences Inc Alcoholes grasos con longitud de cadena media como estimuladores de hematopoyesis.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
CN101878028A (zh) 2007-11-02 2010-11-03 普罗米蒂克生物科学公司 作为肾保护剂的中链长度脂肪酸和甘油酯
NZ586249A (en) * 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
KR20180085825A (ko) * 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) * 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) * 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
AU9221698A (en) * 1997-09-04 1999-03-22 Biozone Laboratories, Inc. Oral liposomal delivery system
EP1030652B1 (en) * 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
ES2238775T3 (es) * 1997-11-19 2005-09-01 Hercules Incorporated Suspensiones polimericas fluidificadas de polisacaridos cationicos en emolientes y su uso en la preparacion de composiciones para el cuidado personal.
EP1061932B1 (en) 1997-11-20 2006-01-25 Gil Ja Jhon Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
SI0937456T1 (en) * 1998-02-23 2004-12-31 Cilag Ag International Erythropoietin liposomal dispersion
DE69910183T2 (de) 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura Darmlösliche sprudelnde zusammensetzungen
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR20020059415A (ko) * 1999-09-27 2002-07-12 스티븐 씨. 큐웨이 토콜-가용성 치료요법제
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001264079A1 (en) 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL158322A0 (en) * 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) * 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
JP5214880B2 (ja) 2003-07-25 2013-06-19 プロメティック、バイオサイエンシーズ、インコーポレーテッド 中鎖脂肪酸の金属塩の製造
KR20070063507A (ko) * 2004-09-03 2007-06-19 프로메틱 바이오사이언시즈 인코포레이티드 면역조절작용과 화학방어활성을 가진 치환된 퓨리닐 유도체및 단독 또는 중쇄 길이 지방산이나 글리세리드와의 혼합사용
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Similar Documents

Publication Publication Date Title
JP2006516987A5 (https=)
ES2255467T1 (es) Acidos grasos de cadena media, gliceridos y analogos como estimuladores de la eritropoyesis.
ES2996688T3 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
RU2010122302A (ru) Жирные кислоты и глицериды со средней длиной цепи в качестве нефропротективных средств
US20130059820A1 (en) Inositol pyrophosphates, and methods of use thereof
KR102265409B1 (ko) 지질 화합물을 이용한 치료방법
JP2011502174A5 (https=)
US6610702B2 (en) Ammonium salts of inositol hexaphosphate, and uses thereof
JP2011519373A (ja) ビニル置換脂肪酸
JP5552314B2 (ja) 新規脂質化合物
US20230321022A1 (en) Reversibly protected thiolated electrophilic fatty acids as prodrugs
JP2010509204A5 (https=)
KR20250060955A (ko) 페롭토시스를 유도하는 조성물 및 방법
KR19990008242A (ko) 니코틴산 에스테르 및 니코틴산 에스테르를 함유한 약품
JP2011502113A (ja) 新規のｄｈａ誘導体およびその医薬品としての用途
US20130261099A1 (en) Fatty Acid Inhibitors
WO2011153353A1 (en) Tocopherol derivatives and methods of use
JP2022521119A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
KR20070108383A (ko) 지질 저하성 화합물
WO2014134053A1 (en) Ascorbate esters of omega-3 fatty acids
AU748861B2 (en) Method of mitigating the adverse effects of interleukin-2
WO2011149766A2 (en) Lipid-tailored pharmaceutical agents
RU2820995C2 (ru) Структурно усиленные жирные кислоты, содержащие кислород, для лечения неалкогольного стеатогепатита
WO2014160936A2 (en) Thiazolidinediones of omega-3 polyunsaturated acids as new insulin sensitizers for treating type2 diabetes
WO2019176693A1 (ja) 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤